BackANI Pharmaceuticals Overview

ANI Pharmaceuticals Long Term Debt

Latest long-term debt for ANIP: $310M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$309.01M
0.70% YoYΔ $2.15M vs prior year quarter

Peer trimmed avg / median

Loading

ANI Pharmaceuticals Long Term Debt History

Loading

ANI Pharmaceuticals vs. peers: Long Term Debt Comparison

Loading

ANI Pharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

ANI Pharmaceuticals (ANIP) FAQ

As of the most recent data (June 2026), ANIP shows a long-term debt of $310M. That compares with $310M in the prior-year period — up 0.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ANIP's long-term debt is now $310M (was $310M) — a 0.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether ANI Pharmaceuticals is outperforming or lagging.

Tracking ANIP's long-term debt over time shows whether ANI Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $310M That compares with $310M in the prior-year period — up 0.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has ANI Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $310M) with ownership activity and broader fundamentals.

ANI Pharmaceuticals's long-term debt is $310M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.